- Home
- BODI vs ELTX Comparison
BODI vs ELTX Comparison
Compare BODI & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BODI
- ELTX
- Stock Information
- Founded
- BODI 1998
- ELTX 2011
- Country
- BODI United States
- ELTX United States
- Employees
- BODI N/A
- ELTX N/A
- Industry
- BODI Industrial Machinery/Components
- ELTX Biotechnology: Pharmaceutical Preparations
- Sector
- BODI Industrials
- ELTX Health Care
- Exchange
- BODI Nasdaq
- ELTX Nasdaq
- Market Cap
- BODI 49.0M
- ELTX 54.6M
- IPO Year
- BODI N/A
- ELTX N/A
- Fundamental
- Price
- BODI $6.51
- ELTX $7.89
- Analyst Decision
- BODI Strong Buy
- ELTX Strong Buy
- Analyst Count
- BODI 3
- ELTX 3
- Target Price
- BODI $12.33
- ELTX $9.50
- AVG Volume (30 Days)
- BODI 14.1K
- ELTX 38.9K
- Earning Date
- BODI 05-05-2025
- ELTX 03-28-2025
- Dividend Yield
- BODI N/A
- ELTX N/A
- EPS Growth
- BODI N/A
- ELTX N/A
- EPS
- BODI N/A
- ELTX N/A
- Revenue
- BODI $451,432,000.00
- ELTX N/A
- Revenue This Year
- BODI N/A
- ELTX N/A
- Revenue Next Year
- BODI N/A
- ELTX N/A
- P/E Ratio
- BODI N/A
- ELTX N/A
- Revenue Growth
- BODI N/A
- ELTX N/A
- 52 Week Low
- BODI $5.14
- ELTX $3.34
- 52 Week High
- BODI $11.31
- ELTX $11.45
- Technical
- Relative Strength Index (RSI)
- BODI 37.98
- ELTX 48.33
- Support Level
- BODI $6.88
- ELTX $7.69
- Resistance Level
- BODI $8.60
- ELTX $8.36
- Average True Range (ATR)
- BODI 0.78
- ELTX 0.57
- MACD
- BODI -0.13
- ELTX -0.11
- Stochastic Oscillator
- BODI 9.39
- ELTX 17.39
About BODI The Beachbody Company Inc. Class A Common Stock
The Beachbody Co Inc is a health and wellness platform providing fitness, nutrition and stress-reducing programs to its customers. The product offerings of the company include Digital Subscriptions, Nutritional Products, and Connected Fitness Products. It earns the majority of its revenue from the United States. The company operates and manages its business in two operating segments, Beachbody and Other.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.